Chengjie Xiong

List of Publications by Year
in descending order

115	4,941	117625	106344
papers	citations	34 h-index	65 g-index

137	137	137	5952
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.8	4
2	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limitsâ€”Application to diagnosing early stage Alzheimer disease. Statistical Methods in Medical Research, 2022, 31, 882-898.	1.5	1
3	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. Alzheimer's and Dementia, 2022, 18, 2570-2581.	0.8	8
4	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
5	Effect of Race on Prediction of Brain Amyloidosis by Plasma AÎ²42/AÎ²40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.1	63
6	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
7	Item response theory analysis of the Clinical Dementia Rating. Alzheimer's and Dementia, 2021, 17, 534-542.	0.8	14
8	Lack of association between acute stroke, post-stroke dementia, race, and Î²-amyloid status. NeuroImage: Clinical, 2021, 29, 102553.	2.7	12
9	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	1.9	27
10	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
11	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	10.2	26
12	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. BMJ Open, 2021, 11, e050820.	1.9	8
13	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 153.	6.2	3
14	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.1	35
15	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
16	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion, 2020, 58, 153-167.	19.1	17
17	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. Neurobiology of Aging, 2020, 96, 165-175.	3.1	13
18	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17

#	Article	IF	Citations
19	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
20	Identifying blood pressure loci whose effects are modulated by multiple lifestyle exposures. Genetic Epidemiology, 2020, 44, 629-641.	1.3	6
21	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.8	13
22	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. Alzheimer's and Dementia, 2020, 16, 589-597.	0.8	25
23	High-precision plasma Î²-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659.	1.1	514
24	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 1149-1159.	0.8	45
25	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.8	7
26	Twoâ€period linear mixed effects models to analyze clinical trials with runâ€in data when the primary outcome is continuous: Applications to Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 450-457.	3.7	2
27	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	7.6	36
28	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.8	72
29	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
30	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. Alzheimer's and Dementia, 2019, 15, 506-514.	0.8	28
31	ICâ€Pâ€046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.8	0
32	Incorporating Biomarkers to Improve Statistical Power of Immunotherapeutic Neoadjuvant Clinical Trials in Patients with Triple-Negative Breast Cancer. Statistics in Biopharmaceutical Research, 2019, 11, 210-219.	0.8	0
33	Reduced nonâ€“rapid eye movement sleep is associated with tau pathology in early Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	12.4	208
34	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	9.0	227
35	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 2019, 75, 42-50.	3.1	36
36	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469.	0.8	192

#	Article	IF	Citations
37	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	7.6	79
38	Assessment of the Genetic Architecture of Alzheimerâ€™s Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756.	2.6	45
39	Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 869-879.	0.8	113
40	Upward drift in cerebrospinal fluid amyloid Î² 42 assay values for more than 10Âyears. Alzheimer's and Dementia, 2018, 14, 62-70.	0.8	50
41	P1â€023: MASS SPECTROMETRYâ€“BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD. Alzheimer's and Dementia, 2018, 14, P273.	0.8	2
42	O3â€14â€01: NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIPâ€1, NEUROGRANIN, SNAPâ€25 AND YKLâ€40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). Alzheimer's and Dementia, 2018, 14, P1059.	0.8	0
43	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14
44	MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-10.	2.7	2
45	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 669-676.	3.7	9
46	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. Annals of Neurology, 2018, 84, 741-753.	5.3	17
47	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
48	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248.	7.6	24
49	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
50	A novel cognitive disease progression model for clinical trials in autosomalâ€dominant Alzheimer's disease. Statistics in Medicine, 2018, 37, 3047-3055.	1.6	31
51	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	2.7	76
52	Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 74-82.	3.7	44
53	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiology of Aging, 2017, 56, 25-32.	3.1	57
54	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	3.3	42

#	Article	IF	Citations
55	Risk of incident clinical diagnosis of Alzheimer's diseaseâ€“type dementiaÂattributable to pathologyâ€confirmed vascular disease. Alzheimer's and Dementia, 2017, 13, 613-623.	0.8	30
56	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
57	[P3â€“263]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER's DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE. Alzheimer's and Dementia, 2017, 13, P1043.	0.8	0
58	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
59	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
60	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
61	[P2â€“209]: QUANTIFYING PRECLINICAL STAGES OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) AND THE ASSOCIATED OVERALL BIOMARKER SIGNATURE ACROSS MODALITIES USING THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). Alzheimer's and Dementia, 2017, 13, P689.	0.8	0
62	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
63	[O2â€“01â€“05]: IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE. Alzheimer's and Dementia, 2017, 13, P550.	0.8	0
64	[O2â€“05â€“03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING. Alzheimer's and Dementia, 2017, 13, P561.	0.8	0
65	[O3â€“10â€“01]: CROSSâ€SECTIONAL AND LONGITUDINAL COMPARISONS OF COGNITION AND BIOMARKERS AMONG COGNITIVELY NORMAL INDIVIDUALS AGED 42 TO 65 YEARS WITH A FAMILY HISTORY OF EITHER AUTOSOMAL DOMINANT AD (ADAD) OR LATEâ€ONSET AD (LOAD). Alzheimer's and Dementia, 2017, 13, P923.	0.8	0
66	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
67	Estimating correlation between multivariate longitudinal data in the presence of heterogeneity. BMC Medical Research Methodology, 2017, 17, 124.	3.1	6
68	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
69	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
70	P4â€004: Planning Dose Escalation in Phase III Clinical Trials May Prevent Underpowered Trials and Mitigate the Increase in Sample Size or Duration of Adaptive Trials. Alzheimer's and Dementia, 2016, 12, P1015.	0.8	0
71	P4â€150: Preclinical Alzheimerâ€™s Disease Predicts Longitudinal Onset of Driving Difficulties Among Cognitively Normal Persons. Alzheimer's and Dementia, 2016, 12, P1071.	0.8	0
72	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0

#	Article	IF	Citations
73	O3-09-05: The Dian-Nacc UDS Comparison Study: Rates of Cognitive Decline. , 2016, 12, P309-P309.		0
74	F4â€03â€02: The Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's and Dementia, 2016, 12, P326.	0.8	0
75	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
76	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiology of Aging, 2016, 43, 23-33.	3.1	49
77	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	5.3	82
78	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	10.2	87
79	A multiple imputation approach to the analysis of clustered interval-censored failure time data with the additive hazards model. Computational Statistics and Data Analysis, 2016, 103, 242-249.	1.2	7
80	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology, 2016, 86, 1499-1506.	1.1	39
81	P1-104: CSF tau predicts working memory and global cognitive decline in autosomal dominant Alzheimer's disease. , 2015, 11, P379-P379.		0
82	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease. , 2015, 11, P255-P255.		0
83	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease. , 2015, 11, P533-P534.		1
84	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
85	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P538-P538.		0
86	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PIB,Âand cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0
87	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	2.6	47
88	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P8-P9.		0
89	Bivariate correlation coefficients in familyâ€type clustered studies. Biometrical Journal, 2015, 57, 1084-1109.	1.0	12
90	Predicting Clinical Binary Outcome Using Multivariate Longitudi nal Data: Application to Patients with Newly Diagnosed Primary Open - Angle Glaucoma. Journal of Biometrics & Biostatistics, 2015, 06, .	4.0	1

#	Article	IF	Citations
91	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	9.0	59
92	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P674-P674.		0
93	P1-106: Longitudinal biomarker connectivity on middle-aged asymptomatic individuals and optimal design on prevention trials of Alzheimer's disease. , 2015, 11, P379-P379.		0
94	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
95	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 2015, 72, 1029.	9.0	237
96	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimerâ€™s disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	6.2	101
97	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.1	27
98	Interrater Reliability of the Record of Driving Errors (RODE). American Journal of Occupational Therapy, 2015, 69, 6902350020p1-6902350020p6.	0.3	10
99	IC-P-008: REGIONAL PIB DEPOSITION AND CSF AÎ²42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P11-P11.		0
100	P1-143: LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT. , 2014, 10, P352-P353.		0
101	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.1	391
102	Optimizing parameters in clinical trials with a randomized start or withdrawal design. Computational Statistics and Data Analysis, 2014, 69, 101-113.	1.2	4
103	S3-01-01: SCREENING FOR ALZHEIMER'S DISEASE IN COGNITIVELY NORMAL OLDER ADULTS: SUBJECTIVE COGNITIVE DECLINE VERSUS INFORMANT REPORT. , 2014, 10, P200-P200.		0
104	O2-05-04: REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY. , 2014, 10, P173-P173.		0
105	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
106	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
107	IC-O2-01: How do we define amyloid positivity in an asymptomatic population? Comparison of CSF, quantitative PET and clinical PET examinations. , 2013, 9, P6-P6.		0
108	Youden Index and Associated Cut-Points for Three Ordinal Diagnostic Groups. Communications in Statistics Part B: Simulation and Computation, 2013, 42, 1213-1234.	1.2	56

#	Article	IF	Citations
109	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. Alzheimer's and Dementia, 2012, 8, P244.	0.8	1
110	O2-01-01: Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer's Disease. , 2011, 7, S287-S287.		0
111	Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study. Archives of Neurology, 2011, 68, 1313.	4.5	55
112	A Parametric Comparison of Diagnostic Accuracy with Three Ordinal Diagnostic Groups. Biometrical Journal, 2007, 49, 682-693.	1.0	22
113	Measuring and estimating diagnostic accuracy when there are three ordinal diagnostic groups. Statistics in Medicine, 2006, 25, 1251-1273.	1.6	84
114	Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. Journal of Applied Statistics, 0, , 1-25.	1.3	2
115	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2